During the past decade, Toyama Prefectural Central Hospital conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 7 clinical trials were completed, i.e. on average, 28% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 7 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toyama Prefectural Central Hospital" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Bayer" with 4 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored and "Haruhiko Fukuda" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toyama Prefectural Central Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 2 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Toyama Prefectural Central Hospital" are "Ulcerative Colitis" (5 trials), "Crohn's Disease" (4 trials), "Colitis, Ulcerative" (2 trials), "Gastric Neoplasm" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Toyama Prefectural Central Hospital" in a lesser frequency.

Most popular intervention types in "Toyama Prefectural Central Hospital" are "Drug" (25 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Mirikizumab" (5 trials), "Guselkumab" (3 trials), "Golimumab" (2 trials) and "JNJ-77242113" (2 trials). Other intervention names were less common.

The vast majority of trials in "Toyama Prefectural Central Hospital" are 29 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Toyama Prefectural Central Hospital". undefined are not yet recruiting, 11 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Toyama Prefectural Central Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Toyama Prefectural Central Hospital, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".